MedAnalytics measures Tofacitinib
market penetration in different clinical practices.
The report is often a source of untapped
market potentials that might exist in own brand marketing.
The market penetration of Tofacitinib varied in different clinical practices.
In recent year 2019, market penetrations was
in Orthopaedic Surgeons, 5% in Internal Medicine Specialists, 4% in
Nephrologists, 4% in Endocrinologists, 3% in Diabetologists, 3% in
Neurologists, 3% in Gastroenterologists, 3% in Dermatologists, 3% in
Physical Medicine Specialists, 3% in Rheumatology Specialists, 2% in
Infertility Specialists, 2% in Pediatric Surgeons, 2% in Neurosurgeons,
2% in Colorectal Surgeons, 2% in Psychiatrists, 2% in cancer surgeons,
2% in General & Laparoscopic Surgeons, 2% in Respiratory Medicine
Specialists, 2% in Cardiologists, 2% in General Physicians, 1% in
Urologists, 1% in Critical Care Medicine Specialists, 1% in ENT
Specialists, 1% in Gynecologists & Obstetricians and 1% in Dentists.
For example, market penetration rate of
a generic found 10% in dermatology practice. It means, 10% dermatology
practitioners are potentials to prescribe this generic. This kind of
report is often a source for discovering an untapped market potentials
that may exist around in marketing own brand.
Request us for your brand report
Brand report includes -
- Present Market share of your brand
- Current & future performance of your brand
- Promotional status of your brand
- Strategic market management of your brand
- And many more